DDX60 has not been studied in detail in cancer, although lower levels in breast cancer are associated with radiosensitivity [71], and high a level of DDX60 is a proposed biomarker and prognostic factor for oral squamous cell carcinoma [72], as well as an indicator of response to immune checkpoint inhibitors in glioma [73]. Here, DDX60 is linked to central nervous system cancer.